Franz Heigl

1.8k total citations
49 papers, 1.1k citations indexed

About

Franz Heigl is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Franz Heigl has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Surgery, 14 papers in Cardiology and Cardiovascular Medicine and 10 papers in Economics and Econometrics. Recurrent topics in Franz Heigl's work include Lipoproteins and Cardiovascular Health (23 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers) and Pharmaceutical Economics and Policy (8 papers). Franz Heigl is often cited by papers focused on Lipoproteins and Cardiovascular Health (23 papers), Antiplatelet Therapy and Cardiovascular Diseases (9 papers) and Pharmaceutical Economics and Policy (8 papers). Franz Heigl collaborates with scholars based in Germany, Japan and United States. Franz Heigl's co-authors include E. Roeseler, Reinhard Klingel, Ulrich Julius, Anja Vogt, Wolfgang Ramlow, Andreas Heibges, Josef Leebmann, Dennis Heutling, Walter Lehmacher and Winfried Maerz and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Franz Heigl

46 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Franz Heigl Germany 18 734 337 215 170 163 49 1.1k
Tommaso Fasano Italy 17 486 0.7× 229 0.7× 176 0.8× 40 0.2× 39 0.2× 41 886
Hok-Hay S. Oei Netherlands 11 440 0.6× 455 1.4× 135 0.6× 14 0.1× 141 0.9× 12 1.2k
Xi Zhao China 16 338 0.5× 256 0.8× 126 0.6× 23 0.1× 64 0.4× 73 865
Evan J. Ryer United States 22 724 1.0× 346 1.0× 68 0.3× 8 0.0× 119 0.7× 70 1.6k
Diego Tejedor Spain 17 401 0.5× 126 0.4× 133 0.6× 24 0.1× 96 0.6× 27 736
Wook-Sung Chung South Korea 15 597 0.8× 756 2.2× 53 0.2× 13 0.1× 73 0.4× 62 1.2k
Iván Ferraz‐Amaro Spain 20 185 0.3× 211 0.6× 57 0.3× 12 0.1× 396 2.4× 144 1.5k
Ki Hong Lee South Korea 17 303 0.4× 555 1.6× 50 0.2× 47 0.3× 56 0.3× 86 904
Josef Veselka Czechia 17 459 0.6× 562 1.7× 34 0.2× 11 0.1× 35 0.2× 96 1.0k
Gabor Sütsch Switzerland 18 950 1.3× 1.6k 4.8× 101 0.5× 8 0.0× 170 1.0× 46 2.3k

Countries citing papers authored by Franz Heigl

Since Specialization
Citations

This map shows the geographic impact of Franz Heigl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franz Heigl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franz Heigl more than expected).

Fields of papers citing papers by Franz Heigl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franz Heigl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franz Heigl. The network helps show where Franz Heigl may publish in the future.

Co-authorship network of co-authors of Franz Heigl

This figure shows the co-authorship network connecting the top 25 collaborators of Franz Heigl. A scholar is included among the top collaborators of Franz Heigl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franz Heigl. Franz Heigl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schettler, Volker, Thomas Zimmermann, Georg Schlieper, et al.. (2024). The German Lipoprotein Apheresis Registry-Summary of the eleventh annual report. Atherosclerosis. 398. 118601–118601. 5 indexed citations
2.
Lapinskas, Tomas, Christoph D. Garlichs, Radu Tanacli, et al.. (2023). Imaging Predictors of Left Ventricular Functional Recovery after Reperfusion Therapy of ST-Elevation Myocardial Infarction Assessed by Cardiac Magnetic Resonance. Journal of Cardiovascular Development and Disease. 10(7). 294–294. 1 indexed citations
3.
Lipphardt, Mark, Bernd Kitze, Franz Heigl, et al.. (2019). Immunoadsorption or plasma exchange in steroid‐refractory multiple sclerosis and neuromyelitis optica. Journal of Clinical Apheresis. 34(4). 381–391. 39 indexed citations
4.
Garlichs, Christoph D., Ahmed Sheriff, Sebastian Kelle, et al.. (2019). STEMI TREATMENT BY CRP REMOVAL PROMISES CLINICAL BENEFIT: FIRST RESULTS OF THE CAMI1 STUDY. Journal of the American College of Cardiology. 73(9). 142–142. 2 indexed citations
5.
6.
Schettler, Volker, C. Neumann, Christian Peter, et al.. (2017). Current insights into the German Lipoprotein Apheresis Registry (GLAR) – Almost 5 years on. Atherosclerosis Supplements. 30. 50–55. 19 indexed citations
7.
Ramlow, Wolfgang, Franz Heigl, J Ringel, et al.. (2017). Efficacy of lipid reduction with DALI and MONET. Atherosclerosis Supplements. 30. 217–224. 5 indexed citations
8.
Kozik–Jaromin, Justyna, Franz Heigl, J Ringel, et al.. (2017). Safety aspects of lipidapheresis using DALI and MONET – Multicenter observational study. Atherosclerosis Supplements. 30. 225–231. 8 indexed citations
9.
Kassner, Ursula, Bastian Salewsky, Adrian Rosada, et al.. (2016). Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. Atherosclerosis. 253. 88–93. 35 indexed citations
10.
11.
12.
Heigl, Franz, et al.. (2013). Immunoadsorption in steroid-refractory multiple sclerosis: Clinical experience in 60 patients. Atherosclerosis Supplements. 14(1). 167–173. 37 indexed citations
13.
Leebmann, Josef, E. Roeseler, Ulrich Julius, et al.. (2013). Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease. Circulation. 128(24). 2567–2576. 232 indexed citations
14.
Grimm, Jochen, Konstantin Nikolaou, Andreas Schindler, et al.. (2012). Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by In Vivo High-Resolution CMR - a comparative analysis. Journal of Cardiovascular Magnetic Resonance. 14(1). 76–76. 16 indexed citations
15.
Canis, Martin, Franz Heigl, & Markus Suckfuell. (2012). Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss. PubMed. 7(S1). 36–40. 19 indexed citations
16.
Heigl, Franz, et al.. (2009). Fibrinogen/LDL apheresis as successful second-line treatment of sudden hearing loss: a retrospective study on 217 patients. Atherosclerosis Supplements. 10(5). 95–101. 23 indexed citations
17.
Jaeger, B.R., Dorothea Nagel, Franz Heigl, et al.. (2009). Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nature Reviews Cardiology. 6(3). 229–239. 225 indexed citations
18.
Heigl, Franz, et al.. (2009). Indication and Implementation of Lipidapheresis, Rheopheresis, or Immunoadsorption (Lessons learnt from Germany's largest apheresis center). Atherosclerosis Supplements. 10(5). 137–141. 9 indexed citations
19.
Canis, Michel, et al.. (2008). H.E.L.P.-Apherese bei der Behandlung des Hörsturzes: Eine Anwendungsbeobachtung an 152 Patienten.. HNO. 56(9). 961–966. 2 indexed citations
20.
Canis, Michel, et al.. (2008). H.E.L.P.-Apherese bei der Behandlung des Hörsturzes. HNO. 56(9). 961–966. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tommaso Fasano Breakdown of academic impact, for papers by Hok-Hay S. Oei Breakdown of academic impact, for papers by Xi Zhao Breakdown of academic impact, for papers by Evan J. Ryer Breakdown of academic impact, for papers by Diego Tejedor Breakdown of academic impact, for papers by Wook-Sung Chung Breakdown of academic impact, for papers by Iván Ferraz‐Amaro Breakdown of academic impact, for papers by Ki Hong Lee Breakdown of academic impact, for papers by Josef Veselka Breakdown of academic impact, for papers by Gabor Sütsch
Rankless by CCL
2026